Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder
This study has been completed.
First Received: April 9, 2004   Last Updated: December 19, 2008   History of Changes
Sponsor: AstraZeneca
Information provided by: AstraZeneca
ClinicalTrials.gov Identifier: NCT00081380
  Purpose

The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar I Disorder. The study consists of enrollment and 2 phases, the Open-label treatment Phase and the Randomized treatment Phase.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.


Condition Intervention Phase
Bipolar Disorder
 Drug: Seroquel®, quetiapine fumarate (atypical antipsychotic)
Drug: lithium (mood stabilizer)
Drug: divalproex (mood stabilizer)
 Phase III

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients (Abbreviated)

Resource links provided by NLM:

MedlinePlus related topics: Bipolar Disorder
Drug Information available for: Quetiapine Quetiapine fumarate Lithium carbonate Lithium citrate
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluate the efficacy of quetiapine versus placebo when used as adjunct therapy to mood stabilizer in increasing time to recurrence of a mood event.

Secondary Outcome Measures:
  • Evaluate the efficacy of quetiapine versus placebo when used as a adjunct therapy to mod stabilizer in increasing time to recurrence of a manic event.

Estimated Enrollment: 710
Study Start Date: March 2004
Study Completion Date: September 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Open-Label

  • A diagnosis of Bipolar I Disorder, Most recent episode Manic (296.4x), or Bipolar I Disorder, Most Recent Episode Depressed (296.5x), or Bipolar I Disorder, Most recent Episode Mixed (296.6x), with or without psychotic features, as defined by Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV)
  • At least 1 manic, depressed, or mixed episode in the 2 years prior to the index episode.
  • Able to understand and comply with the requirements of the study.

Exclusion Criteria:

Open-Label

  • Diagnosis of an anxiety disorder as defined by DSM-IV, which was treated with medication within the past year.
  • Known intolerance or lack of response to quetiapine fumarate or to the assigned mood stabilizer, as judged by the investigator.
  • Previously randomized into this study or D1447C00126
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00081380

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, Arizona
Research Site
Scottsdale, Arizona, United States
United States, Arkansas
Research Site
Little Rock, Arkansas, United States
United States, California
Research Site
Anaheim, California, United States
Research Site
Cerritos, California, United States
Research Site
Orange, California, United States
Research Site
Garden Grove, California, United States
Research Site
La Mesa, California, United States
Research Site
Culver City, California, United States
Research Site
Oceanside, California, United States
Research Site
Chula Vista, California, United States
Research Site
Pico Rivera, California, United States
Research Site
Rosemead, California, United States
Research Site
Riverside, California, United States
Research Site
San Diego, California, United States
Research Site
San Francisco, California, United States
Research Site
Santa Ana, California, United States
United States, Connecticut
Research Site
Farmington, Connecticut, United States
Research Site
New Britain, Connecticut, United States
United States, Florida
Research Site
Jacksonville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
West Palm Beach, Florida, United States
Research Site
Winter Park, Florida, United States
United States, Georgia
Research Site
Atlanta, Georgia, United States
Research Site
Marietta, Georgia, United States
Research Site
Smyrna, Georgia, United States
Research Site
Decatur, Georgia, United States
United States, Hawaii
Research Site
Honolulu, Hawaii, United States
United States, Illinois
Research Site
Chicago, Illinois, United States
Research Site
Hoffman Estates, Illinois, United States
Research Site
Joliet, Illinois, United States
United States, Indiana
Research Site
Evansville, Indiana, United States
Research Site
Greenwood, Indiana, United States
Research Site
Indianapolis, Indiana, United States
United States, Kansas
Research Site
Wichita, Kansas, United States
United States, Kentucky
Research Site
Florence, Kentucky, United States
United States, Louisiana
Research Site
New Orleans, Louisiana, United States
Research Site
Shreveport, Louisiana, United States
Research Site
Lake Charles, Louisiana, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
Research Site
Rockville, Maryland, United States
United States, Massachusetts
Research Site
Pittsfield, Massachusetts, United States
United States, Michigan
Research Site
New Baltimore, Michigan, United States
United States, Missouri
Research Site
St. Louis, Missouri, United States
United States, New Jersey
Research Site
Clementon, New Jersey, United States
Research Site
Moorestown, New Jersey, United States
Research Site
West Caldwell, New Jersey, United States
United States, New Mexico
Research Site
Albuquerque, New Mexico, United States
United States, New York
Research Site
Bronx, New York, United States
Research Site
Brooklyn, New York, United States
Research Site
New York, New York, United States
United States, North Carolina
Research Site
Butner, North Carolina, United States
Research Site
Raleigh, North Carolina, United States
United States, Ohio
Research Site
Beachwood, Ohio, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Dayton, Ohio, United States
Research Site
Medina, Ohio, United States
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Tulsa, Oklahoma, United States
United States, Oregon
Research Site
Eugene, Oregon, United States
Research Site
Portland, Oregon, United States
United States, Pennsylvania
Research Site
Emmaus, Pennsylvania, United States
Research Site
Moon Township, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
United States, South Carolina
Research Site
Charleston, South Carolina, United States
United States, Tennessee
Research Site
Memphis, Tennessee, United States
United States, Texas
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
DeSoto, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Irving, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Wichita Falls, Texas, United States
United States, Virginia
Research Site
Charlottesville, Virginia, United States
Research Site
Falls Church, Virginia, United States
Research Site
Virginia Beach, Virginia, United States
Research Site
Richmond, Virginia, United States
United States, Washington
Research Site
Bellevue, Washington, United States
Research Site
Kirkland, Washington, United States
United States, West Virginia
Research Site
Morgantown, West Virginia, United States
Canada
Research Site
Quebec, Canada
Canada, Alberta
Research Site
Edmonton, Alberta, Canada
Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada
Research Site
Victoria, British Columbia, Canada
Canada, Manitoba
Research Site
Winnipeg, Manitoba, Canada
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Research Site
Hamilton, Ontario, Canada
Research Site
Kingston, Ontario, Canada
Research Site
Markham, Ontario, Canada
Research Site
Mississauga, Ontario, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Canada, Quebec
Research Site
Montreal, Quebec, Canada
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca Seroquel Medical Science Director, MD AstraZeneca
  More Information

No publications provided

Study ID Numbers: D1447C00127
Study First Received: April 9, 2004
Last Updated: December 19, 2008
ClinicalTrials.gov Identifier: NCT00081380     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Bipolar I Disorder
Manic Depressive Disorder
Manic Depression, Mixed

Additional relevant MeSH terms:
Disease
Tranquilizing Agents
Bipolar Disorder
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Antimanic Agents
Antipsychotic Agents
Pharmacologic Actions
 Affective Disorders, Psychotic
Quetiapine
Pathologic Processes
Mental Disorders
Therapeutic Uses
Mood Disorders
Central Nervous System Agents
Lithium

ClinicalTrials.gov processed this record on November 27, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services